GRANTS & FUNDING PROGRAMS AT TRI

In 2015, TRI launched a formal Research Grant Program to support translational research projects based at the institute. The aim is to support researchers progress their discoveries and translate their findings into the clinic.  From 2015-2019, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. TRI is currently reviewing its Grant Program to ensure it maximises the translational support available to researchers based at the institute. The funding opportunity currently available for eligible recipients is:  

TRI Research Funding  

For teams within TRI seeking funding support for their translational research and/or supporting research grant applications. 
If you are interested in applying for support from TRI please contact [email protected] for a link to the application form.  Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:

  1. What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
  2. Previous funding requests to TRI (successful or not) to the same or a different funding body.
  3. How the application meets each of the criteria against which it will be assessed by TRI.
  4. Support from the Institute Director at TRI of the primary applicant (CIA).

Read the full eligibility criteria and terms and conditions here

TRI Grant and Funding Recipients

Year awarded

Grant scheme

Principal Investigator

Project title

2015

Spore

Dr Michelle Hill

Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools

2015

Spore

Dr Antje Blumenthal

Towards biomarkers for patient stratification in sepsis

2015

Spore

Prof Rik Thompson

Portable, single-sided MRI for routine, low-cost analysis of mammographic density

2015

Spore

Prof Ken O'Byrne

Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability

2016

Spore

A/Prof Jyotsna Batra

Novel MicroRNA’s as potential targets for treating prostate cancer

2016

Spore

A/Prof Chamindie Punyadeera

Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy

2018

Spore

Prof Gerald Holtmann

Modulation of the GI Microbiome with probiotics to treat constipation

2018

Spore

Prof John Hooper

Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

2018

Spore

Dr Arutha Kulasinghe

Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer?

2018

Spore

Prof Peter Soyer

Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies

2019

Spore

A/Prof Jyotsna Batra

Improving the PSA test to detect all lethal prostate cancers

2019

Spore

Prof Ben Panizza

Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC)

2019

Drive

Prof Sandro Porceddu

Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer

                                                        

FOR EXTERNAL GRANT AND FUNDING 

Looking for funding for your research project? Visit the Grant and Funding list page for some helpful links to grant and funding opportunities relevant to research projects at TRI.